CVKD vs RTX · $20.2M cap vs P/E 36, rev $46.78B
Cadrenal Therapeutics, Inc. Common Stock (CVKD) versus RTX Corporation (RTX) — a side-by-side from cached financials, not a winner call.
Cadrenal Therapeutics, Inc. Common Stock (CVKD) is a biotechnology company listed on US.
RTX Corporation (RTX) is a aerospace & defense company listed on NYSE. It is led by Chris Calio.
CVKD does not have a complete income-statement cache yet.
Latest reported RTX revenue for 2026-06-30 was $46.78B. Net income was $4.20B. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
CVKD currently screens at market cap $20.2M. RTX currently screens at market cap $259.34B and trailing P/E 36.2.
Not investment advice. Open the CVKD and RTX stock pages for the full models.
Not investment advice.